Webcast – FDA Regulatory Updates and 2020 Outlook for Vaping and Cannabis-Derived Substances

Join partners Ben Haas and Elizabeth Richards for a discussion of FDA regulations surrounding vaping and CBD oversight. MCLE credit offered.

Program

The Maryland District Court’s decision in the American Academy of Pediatrics case and ongoing concerns about youth vaping have raised significant questions regarding the outlook for FDA regulation of these and other tobacco products in 2020. Meanwhile, the 2018 Farm Bill opened the floodgates of a sprawling market for hemp-derived products, challenging FDA’s ability to exert its enforcement authority over this new and burgeoning industry.

During this installment of Latham & Watkins’ We’ve Got Washington Covered webcast series, partners Ben Haas and Elizabeth Richards will examine issues associated with FDA's recent “ban” on flavored e-cigarette products and what to expect in 2020 regarding FDA regulation of vaping. In addition, they will discuss new developments in connection with FDA’s oversight over certain cannabis-derived substances and how these substances may be regulated moving forward.

The featured topics will include:

  • Update on federal regulation of cannabis-derived substances in light of recent USDA rulemaking and FDA enforcement actions, and implications of such actions on currently-marketed CBD products
  • 2020 outlook on regulatory oversight of CBD, including the potential for administrative and legislative action to alter this landscape
  • Update on tobacco litigation and enforcement actions, including the ban on flavored e-cigarettes
  • Implications of the May 2020 premarket application deadline for deemed tobacco products 

Please register to attend.

For questions, please email Chris Hei.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.